Please login to the form below

Not currently logged in
Email:
Password:

CINV

This page shows the latest CINV news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Relypsa. USA. rolapitant. Varubi. chemotherapy-induced nausea and vomiting (CINV). neurokinin-1 receptor antagonist.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Generics aside, competition is building in the CINV sector. Last October the

  • Pharma deals for April 2012 Pharma deals for April 2012

    200. Eli Lilly / Vanda Pharmaceuticals. Licence. VLY-686 (NK-1R) antagonist as novel therapeutic in alcohol dependence or to treat CINV / PONV.

  • GSK files NDA in the US

    FDA). The drug performed well during trials, with results showing that it significantly reduced the number of patients who experienced CINV. ... The company said that 40 to 50 per cent of patients still succumb to breakthrough CINV despite being on

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics